> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Fast Track for Kyverna MS Therapy
- URL: https://www.fdaweb.com/fda-fast-track-for-kyverna-ms-therapy/
- Published: 2024-01-23T12:00:00.000Z
- Updated: 2026-09-14T14:21:00.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156191

FDA has granted fast track designation to Kyverna Therapeutics’ KYV-101, an autologous, fully human CD-19 chimeric antigen receptor (CAR) T-cell product candidate to treat patients with refractory progressive multiple sclerosis. A company [statement](https://kyvernatx.com/press-releases/kyverna-therapeutics-granted-fda-fast-track-designation-for-kyv-101-in-the-treatment-of-patients-with-refractory-progressive-multiple-sclerosis/?ref=fdaweb.com) says KYV-101 specifically targets CD19, a protein expressed on the surface of B cells, which is involved in several types of autoimmune diseases. It says the company plans to continue to explore other indications for the drug.